Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ABL DiagnosticsFRA:9BK0 +0.93%54 EV-to-EBIT is 98.87 as of Sep. 06, 2026, which is 677% above its 10-year median of 12.73. GuruFocus rates FRA:9BK0 with a GF Score™ of 54/100 and a GF Value™ of €7.80 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 474 Healthcare Providers & Services companies, ABL Diagnostics ranks worse than 93.88% on this metric.
The historical rank and industry rank for ABL Diagnostics's EV-to-EBIT or its related term are showing as below:
FRA:9BK0'
s EV-to-EBIT Range Over the Past 10 Years
Min: -312.97 Med: 12.73 Max: 2605.81
Current: 98.87
During the past 13 years, the highest EV-to-EBIT of ABL Diagnostics was 2605.81. The lowest was -312.97. And the median was 12.73.
FRA:9BK0's EV-to-EBIT is ranked worse than 93.88% of 474
companies
in the Healthcare Providers & Services industry
Industry Median: 15.56
vs FRA:9BK0: 98.87
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
ABL Diagnostics's Enterprise Value for the quarter that ended in Dec. 2025 was €45.93 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ABL Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €0.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics EV-to-EBIT Related Terms
ABL Diagnostics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:9BK0 vs VEEV, BTSG, TEM: EV-to-EBIT Comparison
For the Health Information Services subindustry, ABL Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's EV-to-EBIT falls into.
ABL Diagnostics's current Enterprise Value is €39.85 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ABL Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €0.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics (FRA:9BK0) has a EV-to-EBIT of 98.87 as of Sep. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ABL Diagnostics and its competitors. This is 677% above median its historical median of 12.73. According to the industry distribution chart, ABL Diagnostics ranks #445 out of 474 companies in the Healthcare Providers & Services industry, placing it in the top 93.9%.
Is ABL Diagnostics' EV-to-EBIT too high?
ABL Diagnostics' current EV-to-EBIT of 98.87 is 677% above median its 10-year median of 12.73. The Healthcare Providers & Services industry median EV-to-EBIT is 15.56. ABL Diagnostics' value of 98.87 is 535.4% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #445 out of 474 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, ABL Diagnostics has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' EV-to-EBIT compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #445 out of 474 companies for EV-to-EBIT. This places ABL Diagnostics in the lower half of its industry. The industry median EV-to-EBIT is 15.56. ABL Diagnostics' value of 98.87 is 535.4% above this benchmark. While the company's 10-year median is 12.73 vs. the industry median of 15.56, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.56, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current EV-to-EBIT of 98.87 is 535.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current EV-to-EBIT is 98.87, which is 677% above median its own 10-year median of 12.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (FRA:9BK0) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.80, compared to a current price of €2.16 — trading 72.3% below its estimated fair value. The current EV-to-EBIT is 98.87, which is 677% above median its 10-year median of 12.73 and 535.4% above the Healthcare Providers & Services industry median of 15.56. ABL Diagnostics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For ABL Diagnostics (FRA:9BK0), the current EV-to-EBIT is 98.87 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (FRA:9BK0) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.16 is trading 72.3% below its estimated GF Value™ of €7.80.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for FRA:9BK0:
EV-to-EBIT: 98.87 (677% above median its 10-year median of 12.73)
GF Value™: €7.80 vs. price of €2.16 (72.3% below fair value)
Industry Position: 535.4% above the Healthcare Providers & Services median (#445 of 474)
No single metric tells the full story. See the FRA:9BK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
54GF Score
Get the complete analysis for FRA:9BK0
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9BK0 has been successfully added to your 
